Results 71 to 80 of about 31,037 (228)
Synthesis of a Primary Metabolite of Cannabidiol
, 2016 Cannabidiol 1 is the major nonpsychotropic, neutral constituent in most cannabis preparations. It is devoid of the psychoactive properties typical of cannabis; however, it produces numerous, potentially therapeutic pharmacological effects, some of which ...
Susanna Tchilibon (2658169) +1 more
core +1 more source
Cannabidiol-associated hepatotoxicity: a systematic review and meta-analysis.
, 2023 BACKGROUND Findings of liver enzyme elevations in recent cannabidiol studies have raised concerns over liver safety. This study aimed to determine the association between cannabidiol use, liver enzyme elevation, and drug-induced liver injury (DILI ...
Kim, David D +7 more
core +1 more source
Epilepsia, EarlyView.Abstract Objective A multi‐electrode array (MEA) is a powerful extracellular recording technique for long‐term monitoring of neuronal network activity. In recent years, MEA‐based assays have been applied increasingly to evaluate drug efficacy and neurotoxicity, including the assessment of anti‐seizure medications (ASMs). However, systematic comparisons
Griselda Marku +4 more
wiley +1 more source
Frequent cannabis use and the association with seizure burden in drug‐resistant epilepsy
Epilepsia, EarlyView.Abstract Objective Cannabis use has increased substantially, with modern products characterized by high tetrahydrocannabinol concentrations and variable composition. The relationship between frequent cannabis use and epilepsy outcomes remains uncertain. We examined the association between frequent cannabis use and epilepsy severity, clinical phenotype,
Santiago Philibert‐Rosas +16 more
wiley +1 more source
Cannabidiol Reduces Leukemic Cell Size - But Is It Important? [PDF]
, 2017 The anti-cancer effect of the plant-derived cannabinoid, cannabidiol, has been widely demonstrated both in vivo and in vitro. However, this body of preclinical work has not been translated into clinical use.
Kalenderoglou, Nikoletta +2 more
core +4 more sources
Cannabidiol-Based Prodrugs: Synthesis and Bioevaluation
Cannabidiol (CBD 1) is a nonpsychotic cannabinoid-based drug approved by the U.S. FDA for treating refractory epilepsy, namely, Lennox–Gastaut and Dravet syndrome.
Varun Pratap Singh (17797380) +8 more
core +1 more source
Efficacy and Tolerance of Synthetic Cannabidiol for Treatment of Drug Resistant Epilepsy
Frontiers in Neurology, 2019 Objective: Controlled and open label trials have demonstrated efficacy of cannabidiol for certain epileptic encephalopathies. However, plant derived cannabidiol products have been used almost exclusively. Efficacy of synthetically derived cannabidiol has
Kerstin A. Klotz +6 more
doaj +1 more source
Epilepsia, EarlyView.Abstract Anti‐seizure medication (ASM) discovery remains a major challenge despite over 30 commercially available options. One persistent obstacle for any promising candidate compound to successfully move from preclinical study to clinical approval has been the ambiguity in preclinical model selection.
Wolfgang Löscher +1 more
wiley +1 more source
Validation of the diagnosis of Lennox–Gastaut syndrome: Challenges and lessons learned
Epilepsia, EarlyView.Abstract Objective Lennox–Gastaut Syndrome (LGS) is a severe developmental and epileptic encephalopathy characterized by multiple seizure types, cognitive impairment, and distinct electroencephalographic (EEG) findings. However, evolving diagnostic criteria, heterogeneous clinical features, and inconsistent electronic health record (EHR) documentation ...
Nicole Villalba +11 more
wiley +1 more source
Clinical features of the postictal state in adults with epilepsy: A cross‐sectional survey
Epilepsia, EarlyView.Abstract Objective Persons with epilepsy may experience many postictal symptoms after a seizure, which can significantly impact quality of life. We aimed to determine the frequency, duration, and severity of postictal symptoms to better characterize the postictal period.
Ann Subota +12 more
wiley +1 more source